Net inflow of CSPC PHARMA through Hong Kong Stock Connect is HKD 935 millionAASTOCKS·Jan 30 at 04:25 AM09988+7.01%513060-1.14%
GUANGXI LIUYAO GROUP has repurchased a total of 9.7746 million shares at a cost of 180 million yuanZhitong·Nov 3, 2025 at 02:43 AM603368+0.38%
Zhitong A-share lock-up release overview | September 25Zhitong·Sep 24, 2025 at 08:01 PM603368+0.38%605365+4.10%
GUANGXI LIUYAO GROUP held a high-level exchange seminar with Huawei to explore cooperation in pharmaceutical intelligenceZhitong·Sep 11, 2025 at 09:38 PMHUAWEI603368+0.38%
GUANGXI LIUYAO GROUP: The cumulative repurchased shares account for 2.04% of the total share capitalZhitong·Sep 8, 2025 at 03:54 AM603368+0.38%
GUANGXI LIUYAO GROUP plans to repurchase shares worth 100 million to 200 million yuanZhitong·Jul 25, 2025 at 03:47 AM603368+0.38%
GUANGXI LIUYAO GROUP released its 2024 annual performance, with a net profit attributable to the parent company of 855 million yuan, a year-on-year increase of 0.62%Zhitong·Mar 26, 2025 at 03:50 AM603368+0.38%
GUANGXI LIUYAO GROUP established a medical device company that includes health food sales businessZhitong·Jan 2, 2025 at 01:51 AM603368+0.38%
